Julien Sobilo
Centre national de la recherche scientifique
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Julien Sobilo.
International Journal of Cancer | 2012
Marc Vandamme; Eric Robert; Stéphanie Lerondel; Vanessa Sarron; Delphine Ries; Sébastien Dozias; Julien Sobilo; David Gosset; Claudine Kieda; Brigitte Legrain; Jean-Michel Pouvesle; Alain Le Pape
Non‐thermal plasma (NTP) is generated by ionizing neutral gas molecules/atoms leading to a highly reactive gas at ambient temperature containing excited molecules, reactive species and generating transient electric fields. Given its potential to interact with tissue or cells without a significant temperature increase, NTP appears as a promising approach for the treatment of various diseases including cancer. The aim of our study was to evaluate the interest of NTP both in vitro and in vivo. To this end, we evaluated the antitumor activity of NTP in vitro on two human cancer cell lines (glioblastoma U87MG and colorectal carcinoma HCT‐116). Our data showed that NTP generated a large amount of reactive oxygen species (ROS), leading to the formation of DNA damages. This resulted in a multiphase cell cycle arrest and a subsequent apoptosis induction. In addition, in vivo experiments on U87MG bearing mice showed that NTP induced a reduction of bioluminescence and tumor volume as compared to nontreated mice. An induction of apoptosis was also observed together with an accumulation of cells in S phase of the cell cycle suggesting an arrest of tumor proliferation. In conclusion, we demonstrated here that the potential of NTP to generate ROS renders this strategy particularly promising in the context of tumor treatment.
PLOS ONE | 2014
Guenhaël Sanz; Isabelle Leray; Aurélie Dewaele; Julien Sobilo; Stéphanie Lerondel; Stephan Bouet; Denise Grebert; Régine Monnerie; Edith Pajot-Augy; Lluis M. Mir
Olfactory receptors (ORs) are expressed in the olfactory epithelium, where they detect odorants, but also in other tissues with additional functions. Some ORs are even overexpressed in tumor cells. In this study, we identified ORs expressed in enterochromaffin tumor cells by RT-PCR, showing that single cells can co-express several ORs. Some of the receptors identified were already reported in other tumors, but they are orphan (without known ligand), as it is the case for most of the hundreds of human ORs. Thus, genes coding for human ORs with known ligands were transfected into these cells, expressing functional heterologous ORs. The in vitro stimulation of these cells by the corresponding OR odorant agonists promoted cell invasion of collagen gels. Using LNCaP prostate cancer cells, the stimulation of the PSGR (Prostate Specific G protein-coupled Receptor), an endogenously overexpressed OR, by β-ionone, its odorant agonist, resulted in the same phenotypic change. We also showed the involvement of a PI3 kinase γ dependent signaling pathway in this promotion of tumor cell invasiveness triggered by OR stimulation. Finally, after subcutaneous inoculation of LNCaP cells into NSG immunodeficient mice, the in vivo stimulation of these cells by the PSGR agonist β-ionone significantly enhanced metastasis emergence and spreading.
Journal of Controlled Release | 2014
Laurent Guilleminault; Nicolas Azzopardi; Christophe Arnoult; Julien Sobilo; V. Hervé; Jérôme Montharu; A. Guillon; C. Andres; O. Herault; A. Le Pape; P. Diot; Etienne Lemarié; Gilles Paintaud; Valérie Gouilleux-Gruart; Nathalie Heuzé-Vourc'h
Monoclonal antibodies (mAbs) are usually delivered systemically, but only a small proportion of the drug reaches the lung after intravenous injection. The inhalation route is an attractive alternative for the local delivery of mAbs to treat lung diseases, potentially improving tissue concentration and exposure to the drug while limiting passage into the bloodstream and adverse effects. Several studies have shown that the delivery of mAbs or mAb-derived biopharmaceuticals via the airways is feasible and efficient, but little is known about the fate of inhaled mAbs after the deposition of aerosolized particles in the respiratory system. We used cetuximab, an anti-EGFR antibody, as our study model and showed that, after its delivery via the airways, this mAb accumulated rapidly in normal and cancerous tissues in the lung, at concentrations twice those achieved after intravenous delivery, for early time points. The spatial distribution of cetuximab within the tumor was heterogeneous, as reported after i.v. injection. Pharmacokinetic (PK) analyses were carried out in both mice and macaques and showed aerosolized cetuximab bioavailability to be lower and elimination times shorter in macaques than in mice. Using transgenic mice, we showed that FcRn, a key receptor involved in mAb distribution and PK, was likely to make a greater contribution to cetuximab recycling than to the transcytosis of this mAb in the airways. Our results indicate that the inhalation route is potentially useful for the treatment of both acute and chronic lung diseases, to boost and ensure the sustained accumulation of mAbs within the lungs, while limiting their passage into the bloodstream.
Lung Cancer | 2012
S. Iochmann; Stéphanie Lerondel; C. Blechet; Marion Lavergne; Sabrina Pesnel; Julien Sobilo; Nathalie Heuzé-Vourc’h; Alain Le Pape; Pascale Reverdiau
Human small cell lung carcinoma (SCLC) is the most aggressive type of lung cancer but no clinically relevant animal model has been developed to date. Such a model would be valuable to study the molecular aspects of tumour progression and to test the effectiveness of new treatment agents. We generated a reproducible and reliable nude mouse orthotopic model of human SCLC with NCI-H209 tumour cells genetically modified to express firefly luciferase. Cells were analysed for long-term stability of bioluminescence and a clone was passaged twice subcutaneously to enhance tumorigenicity. Cells resuspended in Matrigel and/or EDTA RPMI medium containing a (99m)Tc-labelled tin colloid used as tracer were implanted intrabronchially with a catheter inserted into the trachea and positioned in the main bronchus using X-ray-guided imaging. Deposition of cells into the lung was then assessed by scintigraphy. The growth of the primary tumour was sensitively and non-invasively followed by bioluminescence imaging that allowed real-time monitoring of tumour progression in the same animals over a 2-12-week period. Additional 3D bioluminescence imaging and computed tomography scanning were used to document tumour location and measurements that were confirmed by histological analyses. In conclusion, this original nude mouse orthotopic model resembles various stages of human small cell lung cancer, and therefore could be used to evaluate new treatment strategies.
PLOS ONE | 2016
Florian Raes; Julien Sobilo; Marilyne Le Mée; Stéphanie Rétif; Sharuja Natkunarajah; Stéphanie Lerondel; Alain Le Pape
Objectives We have developed a relevant preclinical model associated with a specific imaging protocol dedicated to onco-pharmacology studies in mice. Materials and Methods We optimized both the animal model and an ultrasound imaging procedure to follow up longitudinally the lung tumor growth in mice. Moreover we proposed to measure by photoacoustic imaging the intratumoral hypoxia, which is a crucial parameter responsible for resistance to therapies. Finally, we compared ultrasound data to x-ray micro computed tomography and volumetric measurements to validate the relevance of this approach on the NCI-H460 human orthotopic lung tumor. Results This study demonstrates the ability of ultrasound imaging to detect and monitor the in vivo orthotopic lung tumor growth by high resolution ultrasound imaging. This approach enabled us to characterize key biological parameters such as oxygenation, perfusion status and vascularization of tumors. Conclusion Such an experimental approach has never been reported previously and it would provide a nonradiative tool for assessment of anticancer therapeutic efficacy in mice. Considering the absence of ultrasound propagation through the lung parenchyma, this strategy requires the implantation of tumors strictly located in the superficial posterior part of the lung.
FEBS Open Bio | 2013
Marion Lavergne; Marie-Lise Jourdan; Claire Bléchet; Serge Guyétant; Alain Le Pape; Nathalie Heuzé-Vourc’h; Yves Courty; Stéphanie Lerondel; Julien Sobilo; S. Iochmann; Pascale Reverdiau
Tissue factor pathway inhibitor‐2 (TFPI‐2) is a potent inhibitor of plasmin, a protease which is involved in tumour progression by activating (MMPs). This therefore makes TFPI‐2 a potential inhibitor of invasiveness and the development of metastases. In this study, low levels of TFPI‐2 expression were found in 65% of patients with small cell lung cancer (SCLC), the most aggressive type of lung cancer. To study the impact of TFPI‐2 in tumour progression, TFPI‐2 was overexpressed in NCI‐H209 SCLC cells which were orthotopically implanted in nude mice. Investigations showed that TFPI‐2 inhibited lung tumour growth. Such inhibition could be explained in vitro by a decrease in tumour cell viability, blockade of G1/S phase cell cycle transition and an increase in apoptosis shown in NCI‐H209 cells expressing TFPI‐2. We also demonstrated that TFPI‐2 upregulation in NCI‐H209 cells decreased MMP expression, particularly by downregulating MMP‐1 and MMP‐3. Moreover, TFPI‐2 inhibited phosphorylation of the MAPK signalling pathway proteins involved in the induction of MMP transcripts, among which MMP‐1 was predominant in SCLC tissues and was inversely expressed with TFPI‐2 in 35% of cases. These results suggest that downregulation of TFPI‐2 expression could favour the development of SCLC.
PLOS ONE | 2017
Viorel Simion; Julien Sobilo; Rudy Clemoncon; Sharuja Natkunarajah; Safia Ezzine; Florence Abdallah; Stéphanie Lerondel; Chantal Pichon; Patrick Baril
MicroRNAs (miRNAs) are key players in many biological processes and are considered as an emerging class of pharmacology drugs for diagnosis and therapy. However to fully exploit the therapeutic potential of miRNAs, it is becoming crucial to monitor their expression pattern using medical imaging modalities. Recently, we developed a method called RILES, for RNAi-Inducible Luciferase Expression System that relies on an engineered regulatable expression system to switch-ON the expression of the luciferase gene when a miRNA of interest is expressed in cells. Here we investigated whether replacing the luciferase reporter gene with the human sodium iodide symporter (hNIS) reporter gene will be also suited to monitor the expression of miRNAs in a clinical setting context. We provide evidence that radionuclide imaging of miRNA expression using hNIS is feasible although it is not as robust as when the luciferase reporter gene is used. However, under appropriate conditions, we monitored the expression of several miRNAs in cells, in the liver and in the tibialis anterior muscle of mice undergoing muscular atrophy. We demonstrated that radiotracer accumulation in transfected cells correlated with the induction of hNIS and with the expression of miRNAs detected by real time PCR. We established the kinetic of miRNA-23a expression in mice and demonstrated that this miRNA follows a biphasic expression pattern characterized by a loss of expression at a late time point of muscular atrophy. At autopsy, we found an opposite expression pattern between miRNA-23a and one of the main transcriptional target of this miRNA, APAF-1, and as downstream target, Caspase 9. Our results report the first positive monitoring of endogenously expressed miRNAs in a nuclear medicine imaging context and support the development of additional work to establish the potential therapeutic value of miRNA-23 to prevent the damaging effects of muscular atrophy.
Chemical Communications | 2018
Kyangwi P. Malikidogo; Isidro Da Silva; Jean-François Morfin; Sara Lacerda; Laurent Barantin; Thierry Sauvage; Julien Sobilo; Stéphanie Lerondel; Éva Tóth; Célia S. Bonnet
We propose quantitative assessment of zinc by combining nuclear and MR imaging. We use a cocktail of a Gd3+-complex providing a Zn2+-dependent MRI response and its 165Er3+ analogue allowing for concentration assessment. 165Er is readily obtained in a cyclotron and purified, which is indispensable for successful quantification of metal ions.
Cancer Research | 2016
Florian Raes; Julien Sobilo; Sharuja Natkunarajah; Philippe Trochet; Dieter Fuchs; Stéphanie Lerondel; Alain Le Pape
Introduction The aim of this study is to develop new strategies for the exploration of relevant preclinical lung tumor models dedicated to onco-pharmacology studies in mice. Here we refine a translational approach while overcoming physical ultrasound (US) imaging limitations allowing lung tumors exploration. Our data were compared to Computed Tomography (CT) and Bioluminescence (BLI) aiming to validate this promising approach. Methods Human lung cancer cells NCI-H460-luc2 were orthotopically xenografted in Balb/c nude mice. BLI was performed 7 days after implantation then once a week until the end of the study (Day 28) using an IVIS-Lumina II (Perkin Elmer). Tumors were imaged with the Vevo®LAZR System (FUJIFILM VisualSonics Inc.), 3D scans of US, Contrast Enhanced Ultrasound (CEUS) (Vevo MicroMarkerTM) and photoacoustic (PA) image being recorded digitally. A comparison between in vivo US and CT was achieved with additional ex vivo weight and volumetric measurements. Results The control of the tumor cell implantation was determined by BLI allowing the early quantification of tumor burden. 3D US measurements made possible longitudinal tumor volumes assessment. Compared to the other in vivo measurements, results clearly indicated the gross correlation of volumes processed with US and CT (R2 = 0.75). Such a correlation is also observed with ex vivo US weight and volumetric measurements (R2 = 0.72, R2 = 0.75 and R2 = 0.65 respectively). PA imaging evidenced the hemoglobin saturation with oxygen inside tumors, and targeted CEUS imaging allowed assessing the relative VEGFR2 expression in lung tumors. Conclusions This study proved the ability of US imaging to detect and control the in vivo orthotopic lung tumor growth. This real-time approach is fast while being completely inert regarding the in situ proliferation, as compared to dosimetry related to repeated CT examinations. Furthermore it allows overcoming the limitation of BLI at the time tumors become hypoxic since the luciferase/luciferin reaction is strictly dependent upon O2 and ATP. We described here a PA and US imaging strategy to follow the orthotopic lung tumors growth and consider biomarkers such as VEGFR2 expression or hypoxia in vivo for the first time. This procedure would be of great interest to longitudinally investigate tumor proliferation in animals when evaluating new anticancer therapies efficacy, avoiding any perturbation of the tumor progression compared to other available imaging modalities. Citation Format: Florian Raes, Julien Sobilo, Sharuja Natkunarajah, Philippe Trochet, Dieter Fuchs, Stephanie Lerondel, Alain Le Pape. Novel imaging strategy to assess the antitumor efficacy of treatments in an orthotopic mouse lung cancer model using ultrasound and photoacoustic imaging. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4200.
Plasma Processes and Polymers | 2010
Marc Vandamme; Eric Robert; Sabrina Pesnel; Emerson Barbosa; Sébastien Dozias; Julien Sobilo; Stéphanie Lerondel; Alain Le Pape; Jean Michel Pouvesle